You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,839,631


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,839,631 protect, and when does it expire?

Patent 9,839,631 protects XEGLYZE and is included in one NDA.

This patent has twenty-six patent family members in fourteen countries.

Summary for Patent: 9,839,631
Patent landscape, scope, and claims:
Title:Methods and compositions for controlling ectoparasites
Abstract: A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided.
Inventor(s): Bowles; Vernon Morrison (Glen Iris, AU)
Assignee: DR. REDDY'S LABORATORIES, S.A. (Basel, CH)
Application Number:15/172,343
Patent Claim Types:
see list of patent claims
Use;

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,839,631

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hatchtech XEGLYZE abametapir LOTION;TOPICAL 206966-001 Jul 24, 2020 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y Y TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,839,631

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2003903686Jul 16, 2003

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.